ArticleIranian Red Crescent medical journal2013
HER2 Ile655Val Single Nucleotide Polymorphism in Patients with Ovarian Cancer.
Article in Iranian Red Crescent medical journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.
- The association between single nucleotide polymorphisms and ovarian cancer risk: A systematic review and network meta-analysis.Cancer medicine · 2023Pooled it
- Her2Scientific reports · 2018Pooled it
- Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.OncoTargets and therapy · 2018Article
- Association of HER2 codon 655 polymorphism with ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between HER2 Ile655Val single nucleotide polymorphism and cancer is controversial.
objectivesThe aim of our study was to investigate this polymorphism in patients with ovarian cancer. PATIENTS AND
methodsGenomic DNA was extracted from peripheral blood leukocytes of 107 patients and 130 healthy women. HER2 gene polymorphism was assessed by PCR-RFLP.
resultsNo significant difference was observed in genotype and allele frequency between patient and control groups according to HER2 Ile655Val polymorphism. The disease stage, age, and histological type were also not associated with the polymorphism.
conclusionsOur data showed that HER2 Ile655Val single nucleotide polymorphism was not significantly associated with onset, histological type, age, and stage of ovarian cancer in Iranian patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.